Treatment of the premenstrual syndrome: A double blind placebo controlled cross over study using danazol

Publisher Website
Google Scholar
Abstract
A double blind placebo controlled cross over study was conducted to assess the response of women with severe premenstrual syndrome to treatment with danazol. Daily self assessment of clinical state was measured using the Moos menstrual distress questionnaire. The data were analysed for the Moos symptoms clusters and the most prevalent individual symptoms using the Wilcoxon matched pairs test. Most of the common premenstrual symptoms improved to a statistically greater extent with danazol than with placebo. Despite the incidence of minor side effects danazol, 400 mg/day, proved to be an effective symptomatic treatment for the premenstrual syndrome and should be considered in the management of women with severe symptoms, or in those who are resistant to other forms of treatment.

This publication has 13 references indexed in Scilit: